The possible reason for this is that EGFR-mutated NSCLC usually has a lower level of PD-L1 expression (9, 10), and NSCLC patients carrying EGFR mutations with PD-L1 TPS greater than 50% account for approximately 11.8% of all non-small cell lung cancers. This evidence concerns the gene EGFR and non-small cell lung carcinoma.